leisure time -WSS

leisure time

author：leisure time 2025-10-01 18:45:03 - browse：236

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： AstraZeneca lung cancer study comes in below expectations

entertainment

WSS

Beware reading your test results before your doctor does

NIH study of ME/CFS points to clear biological hallmarks

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Dario to buy mental health app maker Twill in cash and stock deal

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Alabama hospital puts IVF treatments on hold

leisure time

leisure time

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

Fatty liver disease was alleviated by Lilly’s ‘triple

New air purifier tech could be key to improving indoor air quality

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Psychedelics group wrestles with new pharma identity

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Malaria cases in Florida and Texas: Here’s what you need to know

6 phony surgeries that take placebo to the extreme

Medical records are filled with copy

R1 RCM gets $5.8 billion buyout offer from private equity firm

knowledge

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

A new nitrogen execution bill also undermines medical licensing

Why palliative psychiatry is worth discussing

The biotech scorecard for Q3: 15 stock

How Robert F. Kennedy Jr. distorted vaccine science

What affirmative action's end means to a medical student

entertainment

focus

hotspot

entertainment